Nirmatrelvir/ritonavir: real world drug-drug interaction management experience
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Background
In the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug–drug interactions.
Research design and methods
We analyzed real-world drug–drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.
Results
Among 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.
Conclusions
This highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.
In the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug–drug interactions.
Research design and methods
We analyzed real-world drug–drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.
Results
Among 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.
Conclusions
This highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.
Date Issued
2024-09
Date Acceptance
2024-08-05
Citation
Expert Review of Anti-infective Therapy, 2024, 22 (9), pp.781-783
ISSN
1478-7210
Publisher
Taylor and Francis Group
Start Page
781
End Page
783
Journal / Book Title
Expert Review of Anti-infective Therapy
Volume
22
Issue
9
Copyright Statement
© 2024 Informa UK Limited, trading as Taylor & Francis Group. This is the author’s accepted manuscript made available under a CC-BY licence in accordance with Imperial’s Research Publications Open Access policy (www.imperial.ac.uk/oa-policy)
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/39109469
Subjects
COVID-19
drug–drug interactions
Nirmatrelvir/ritonavir
Paxlovid
real world
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2024-08-22